Signaturefd LLC Buys 257 Shares of Hologic, Inc. (NASDAQ:HOLX)

Signaturefd LLC boosted its stake in Hologic, Inc. (NASDAQ:HOLX) by 13.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,186 shares of the medical equipment provider’s stock after purchasing an additional 257 shares during the quarter. Signaturefd LLC’s holdings in Hologic were worth $178,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Sequoia Financial Advisors LLC boosted its holdings in Hologic by 2.4% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 7,388 shares of the medical equipment provider’s stock valued at $602,000 after purchasing an additional 173 shares during the period. Everence Capital Management Inc. purchased a new stake in shares of Hologic in the third quarter worth $389,000. Prentiss Smith & Co. Inc. boosted its stake in Hologic by 0.3% during the third quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock valued at $3,967,000 after buying an additional 130 shares during the period. Allspring Global Investments Holdings LLC grew its position in Hologic by 18.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 297,229 shares of the medical equipment provider’s stock worth $24,212,000 after buying an additional 45,360 shares in the last quarter. Finally, OLD National Bancorp IN bought a new position in Hologic in the 3rd quarter worth about $204,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Insider Transactions at Hologic

In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the completion of the sale, the insider now owns 10,476 shares of the company’s stock, valued at $858,927.24. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the transaction, the insider now owns 3,735 shares in the company, valued at $310,415.85. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the completion of the sale, the insider now directly owns 10,476 shares of the company’s stock, valued at $858,927.24. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.75% of the company’s stock.

Hologic Stock Down 0.1 %

Shares of NASDAQ:HOLX opened at $80.83 on Monday. The stock has a market capitalization of $18.77 billion, a P/E ratio of 27.49, a price-to-earnings-growth ratio of 2.96 and a beta of 0.98. The stock’s 50-day moving average price is $80.92 and its 200-day moving average price is $77.86. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same period last year, the company earned $0.93 EPS. Hologic’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, equities analysts anticipate that Hologic, Inc. will post 4.09 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on HOLX shares. Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Tuesday, October 15th. Mizuho increased their price target on shares of Hologic from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Friday, October 4th. Royal Bank of Canada restated a “sector perform” rating and set a $82.00 price objective on shares of Hologic in a research report on Friday, August 16th. Evercore ISI upped their target price on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research report on Tuesday, October 1st. Finally, Stephens restated an “overweight” rating and set a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Hologic presently has a consensus rating of “Moderate Buy” and an average price target of $87.50.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.